Advertisement

Hämostyptika

  • J. Koscielny
  • C. Jámbor
  • C. F. Weber
  • P. Hellstern
  • C. von Heymann
  • A. Greinacher
  • H.-G. Kopp
  • R. Möhle
  • L. Kanz
Chapter
  • 3.1k Downloads

Zusammenfassung

Desmopressin (DDAVP) wurde 1966 als Abkömmling des antidiuretischen Hypophysenhormons Arginin-Vasopressin synthetisch hergestellt. Zu den antidiuretischen Indikationen zählen Diabetes insipidus und Enuresis nocturna, zudem wird es in Tests zur Bestimmung der Nierenkonzentrationsfähigkeit verwendet

Literatur

  1. Balduini CL, Noris P, Belletti S, Spedini P, Gamba G (1999) In vitro and in vivo effects of desmopressin on platelet function. Haematologica 84: 891–896PubMedGoogle Scholar
  2. Burroughs AK, Matthews K, Qadiri M, Thomas N, Kernoff P, Tuddenham E, McIntyre N (1985) Desmopressin and bleeding time in patients with cirrhosis. Br Med J (Clin Res Ed) 291(6506): 1377–81CrossRefGoogle Scholar
  3. Budde U, Schaefer G, Mueller N, Egli H, Dent J, Ruggeri Z, Zimmerman T (1984) Acquired von Willebrand’s disease in the myeloproliferative syndrome. Blood 64(5): 981–5PubMedGoogle Scholar
  4. Carless PA, Henry DA, Moxey AJ, O’Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D (2006) Desmopressin for minimizing perioperative allogeneic blood transfusion (Review). Cochrane Library, Issue 3 1–40Google Scholar
  5. De La Fuente B et al. (1985) Response of patients with mild and moderate hemophilia Aand von Willebrand disease to treatment with desmopressin. Ann Int Med 103: 6–14PubMedGoogle Scholar
  6. De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM (1986) von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest 77(4): 1272–7PubMedCrossRefGoogle Scholar
  7. Despotis GJ et al. (1999) Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet 354(9173): 106–10PubMedCrossRefGoogle Scholar
  8. Emmeis JJ, van den Eijnden-Schrauwen Y, van den Hoogen CM, de Priester W, Westmuckett A, Lupu F (1997) An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 139: 245–56CrossRefGoogle Scholar
  9. Franchini M (2007) The use of desmopressin as a hemostatic agent: A concise review. Am J Hematol 82: 822–825Google Scholar
  10. Franchini M, Giuseppe L, Veneri D (2006) Efficacy of desmopressin in preventing hemorrhagic complications in a patient with Marfan syndrome undergoing cardiac surgery Blood Coagul Fibrinolysis 17: 325–326PubMedCrossRefGoogle Scholar
  11. Ibbotson SH, Grant PJ, Kerry R, Findlay VS, Prentice CR (1991) The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro. Thromb Haemost 65(1): 64–6PubMedGoogle Scholar
  12. Johnstone MT, Andrews T, Ware JA, Rudd MA, George D, Weinstein M, Loscalzo J (1990) Bleeding time prolongation with streptokinase and its reduction with 1-desamino-8-D-arginine vasopressin. Circulation 82(6): 2142–51PubMedGoogle Scholar
  13. Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck KL, Kubes P (1995) Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. Blood 86: 2760–2766PubMedGoogle Scholar
  14. Kauffmann JE, Iezzi M, Vischer UM (2003) Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor-and cAMP-mediating signalling. J Thromb Haemos 1: 821–828CrossRefGoogle Scholar
  15. Kesteven PJ, Holland LJ, Lawrie AS, Savidge GF (1984) Inhibitor to factor VIII in mild haemophilia. Thromb Haemost 52(1): 50–2PubMedGoogle Scholar
  16. Kobrinsky NL et al. (1984) Shortening of bleeding time by 1-desamino-8-D-arginine vasopressin in various bleeding disorders. Lancet 1: 1145–1148PubMedCrossRefGoogle Scholar
  17. Koscielny J, Kiesewetter H, Tempelhoff GF (2006) Platelet Function Analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemostasis 4: 1426–27CrossRefGoogle Scholar
  18. Koscielny J, Tempelhoff GF, Ziemer S, Radtke H, Schmutzler M, Sinha P, Salama A, Kiesewetter H, Latza R (2004) A Practical Concept for Preoperative Management in Patients with Impaired Primary Hemostasis. Clinical and Applied Thrombosis/Hemostasis 10: 155–166PubMedCrossRefGoogle Scholar
  19. Koscielny J, Blaicher AM, Felfernig D, Latza R, Wenzel E, Kiesewetter H (1998) Consensus use of desmopressin and antifibrinolytics in three university clinics. Anaesthesia 53: 60–62PubMedGoogle Scholar
  20. Koscielny J, Radtke H, Ziemer S, Pindur G, Jung F, Kiesewetter H, Wenzel E (1995) Normalisierung der Thrombozytenfunktion durch Desmopressin. Präoperativer Einsatz bei durch Acetylsalicylsäure (ASS) und nichtsteroidale Analgetika induzierter Thrombozytopathie. Anästh Intensivmed 36: 205–210Google Scholar
  21. Lazarchick J, Conroy JM (1995) The effect of 6% hydroxyethyl starch and desmopressin infusion on von Willebrand factor: ristocetin cofactor activity. Ann Clin Lab Sci 25(4): 306–9PubMedGoogle Scholar
  22. Lethagen S, Nilsson IM (1992) DDAVP-induced enhancement of platelet retention: its dependence on platelet-von Willebrand factor and the platelet receptor GP IIb/IIIa. Eur J Haematol 42: 7–13Google Scholar
  23. Lethagen S et al. (1990) Effects of desmopressin acetate (DDAVP) and dextran on hemostatic and thromboprophylactic mechanisms. Acta Chir Scand 156: 597–602PubMedGoogle Scholar
  24. Mannucci PM (2004) Treatment of von Willebrand’ s Disease. N Engl J Med 351(7): 683–94PubMedCrossRefGoogle Scholar
  25. Mannucci PM, Carlsson S, Harris AS (1994) Desmopressin, surgery and thrombosis. Thromb Haemost 71: 154–155PubMedGoogle Scholar
  26. Mannucci PM (1988) Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 72: 1449–1455PubMedGoogle Scholar
  27. Mannucci PM (1986) Desmopressin (DDAVP) for treatment of disorders of hemostasis. Progr Hemost Thromb 8: 19–45Google Scholar
  28. Mannucci PM et al. (1983) Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Eng J Med 308: 8–12Google Scholar
  29. Mannucci PM et al. (1977) DDAVP: a new pharmacological approach to the management of hemophilia and von Willebrand disease. Lancet 1: 869–872PubMedCrossRefGoogle Scholar
  30. Mannucci PM et al. (1976) Studies on the prolonged bleeding time in von Willebrand disease. J Lab Clin Med 88: 662–671PubMedGoogle Scholar
  31. Marti GE, Rick ME, Sidbury J, Gralnick HR (1986) DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding times. Blood 68(1): 180–4PubMedGoogle Scholar
  32. Pereira A, del Valle Onorato M, Sanz C (2003) DDAVP enhances the ability of blood monocytes to form rosettes with activated platelets by increasing the expression of P-selectin sialylated ligands on the monocyte surface. Br J Haematol 120: 814–20PubMedCrossRefGoogle Scholar
  33. Pfueller SL, Howard MA, White JG, Menon C, Berry EW (1987) Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome. Thromb Haemost 58(4): 1060–3PubMedGoogle Scholar
  34. Rodeghiero F (1989) Consistency of responses to repeated DDAVP infusions in patients with von Willebrand disease and hemophilia A. Blood 74: 1997–2000PubMedGoogle Scholar
  35. Sakariassen KS, Cattaneo M, Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ (1995) DDAVP enhancesplatelet adherence and platelet microplates and enhanced procoagulant activity. Thromb Res 79: 163–174CrossRefGoogle Scholar
  36. Salzman EW, Weinstein MJ, Weintraub RM, et al. (1986) Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: A double-blind randomized trial. N Engl J Med 314: 1402–1406PubMedGoogle Scholar
  37. Schulman S (1991) DDAVP — The multipotent drug in patients with coagulopathies. Transfusion Med Rev 2: 132–144Google Scholar
  38. Schulman S, Johnsson H (1991) Heparin, DDAVP and the bleeding time. Thromb Haemost 65: 242–244PubMedGoogle Scholar
  39. Sloand EM, Alyono D, Klein HG (1994) 1-deamino-8-D-arginine vasopressin (DDAVP) increasesplatelet membrane expression of glycoprotein Ib in patients with disorders of platelet functionand after cardiopulmonary bypass. Am J Hematol 46: 199–207PubMedCrossRefGoogle Scholar
  40. Theiss W, Sauer E (1977) DDAVP: alternative to replacement treatment in mild haemophilia A and von Willebrand-Jurgens syndrome Dtsch Med Wochenschr 102(48): 1769–72PubMedCrossRefGoogle Scholar
  41. Von Blohn G, Kohler M, Hellstern P, Miyashita C, Wenzel E (1986) Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP). Thromb Haemost 55(1): 108–11Google Scholar
  42. Watson AJ, Keogh JA (1982) Effect of 1-deamino-8-D-arginine vasopressin on the prolonged bleeding time in chronic renal failure. Nephron 32(1): 49–52PubMedCrossRefGoogle Scholar

Literatur

  1. Bartholomew JR, Salgia R, Bell WR (1989) Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med 149(9): 1959–61PubMedCrossRefGoogle Scholar
  2. Baubillier E, Cherqui D, Dominique C, Khalil M, Bonnet F, Fagniez PL, Duvaldestin P (1994) A fatal thrombotic complication during liver transplantation after aprotinin administration. Transplantation 57(11): 1664–6PubMedGoogle Scholar
  3. Beierlein W, Scheule AM, Dietrich W, Ziemer G (2005) Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann Thorac Surg 79(2): 741–8PubMedCrossRefGoogle Scholar
  4. Bonnar J, Sheppard BL (1996) Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 313(7057): 579–82PubMedGoogle Scholar
  5. Brown JR, Birkmeyer NJ, O’Connor GT (2007) Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115(22): 2801–13PubMedCrossRefGoogle Scholar
  6. Chabbat J, Porte P, Tellier M, Steinbuch M (1993) Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complex. Thromb Res 71(3): 205–15PubMedCrossRefGoogle Scholar
  7. Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, Gresele P (2003) Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 38(1): 230–7PubMedCrossRefGoogle Scholar
  8. Cramer EM, Lu H, Caen JP, Soria C, Berndt MC, Tenza D (1991) Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation. Blood 77(4): 694–9PubMedGoogle Scholar
  9. Dowd NP, Karski JM, Cheng DC, Carroll JA, Lin Y, James RL, Butterworth J (2002) Pharmacokinetics of tranexamic acid during cardiopulmonary bypass. Anesthesiology 97(2): 390–9PubMedCrossRefGoogle Scholar
  10. Fergusson DA, Hebert PC, Mazer CD et al. (2008) A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358: 2319–31PubMedCrossRefGoogle Scholar
  11. Fitzsimons MG, Peterfreund RA, Raines DE (2001) Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation: report of two cases. Anesth Analg 92(6): 1418–21PubMedCrossRefGoogle Scholar
  12. Forbes CD, Barr RD, Reid G, Thomson C, Prentice CR, McNicol GP, Douglas AS (1972) Tranexamic acid in control of haemorrhage after dental extraction in haemophilia and Christmas disease. Br Med J 2(5809): 311–3PubMedCrossRefGoogle Scholar
  13. Görlinger K (2006) Gerinnungsmanagement bei Lebertransplantationen. Hämostaseologie 26(3 Suppl 1): S64–76PubMedGoogle Scholar
  14. Görlinger K, Vorweg M, Hanke A, Monaca E, Wappler F, Peters J (2006) Gerinnungsmanagement beim Polytrauma auf der Grundlage eines ROTEM-basierten Algorithmus. Intensivmed 43(Suppl1): 87Google Scholar
  15. Groenland TH, Porte RJ (2006) Antifibrinolytics in liver transplantation. Int Anesthesiol Clin 44(3): 83–97PubMedCrossRefGoogle Scholar
  16. Hellstern P (2004) Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 11(5): 346–50PubMedCrossRefGoogle Scholar
  17. Henry DA, Moxey AJ, Carless PA, O’Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D (2001) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev (1): CD001886Google Scholar
  18. Henry DA, O’Connell DL (1989) Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage. BMJ 298(6681): 1142–6PubMedCrossRefGoogle Scholar
  19. Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA (1996) Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg 83(4): 696–700PubMedCrossRefGoogle Scholar
  20. Jambor C, Görlinger K (2007) Einsatz von Antifibrinolytika bei Massivtransfusionen. A&I 48: 167–173Google Scholar
  21. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, Wijeysundera DN, Fedorko L, Yau TM (2006) A propensity score case-control comparison of aprotinin and tranexamic acid in hightransfusion-risk cardiac surgery. Transfusion 46(3): 327–38PubMedCrossRefGoogle Scholar
  22. Khan MM, Gikakis N, Miyamoto S, Rao AK, Cooper SL, Edmunds LH Jr, Colman RW (1999) Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass. Ann Thorac Surg 68(2): 473–8PubMedCrossRefGoogle Scholar
  23. Landis RC, Haskard DO, Taylor KM (2001) New antiinflammatory and platelet-preserving effects of aprotinin. Ann Thorac Surg 72(5): S1808–13PubMedCrossRefGoogle Scholar
  24. Lang T, von Depka M (2006) Possibilities and limitations of thrombelastometry/-graphy. Hamostaseologie 26(3 Suppl 1): S20–9PubMedGoogle Scholar
  25. Laupacis A, Fergusson D (1997) Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 85(6): 1258–67PubMedCrossRefGoogle Scholar
  26. Lucas-Polomeni MM, Delaval Y, Menestret P, Delaval P, Ecoffey C (2004) A case of anaphylactic shock with tranexamique acid (Exacyl). Ann Fr Anesth Reanim 23(6): 607–9PubMedGoogle Scholar
  27. Mangano DT, Miao Y, Vuylsteke A et al. (2007) Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. Jama 297(5): 471–9PubMedCrossRefGoogle Scholar
  28. Mangano DT, Tudor IC, Dietzel C (2006) The risk associated with aprotinin in cardiac surgery. N Engl J Med 354(4): 353–65PubMedCrossRefGoogle Scholar
  29. Mannucci PM (1998) Hemostatic drugs. N Engl J Med 339(4): 245–53PubMedCrossRefGoogle Scholar
  30. Mojcik CF, Levy JH (2001) Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg 71(2): 745–54PubMedCrossRefGoogle Scholar
  31. Oudijk EJ, Nieuwenhuis HK, Bos R, Fijnheer R (2000) Elastase mediated fibrinolysis in acute promyelocytic leukemia. Thromb Haemost 83(6): 906–8PubMedGoogle Scholar
  32. Paparella D, Brister SJ, Buchanan MR (2004) Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 30(10): 1873–81PubMedCrossRefGoogle Scholar
  33. Pfanner G, Kilgert K (2006) Haemorrhagic complications in obstetrics. Hamostaseologie 26(3 Suppl 1): S56–63PubMedGoogle Scholar
  34. Pietsch UC, Schaffranietz L (2006) Anaesthesiological management in orthotopic liver transplantation — results of a survey. Anasthesiol Intensivmed Notfallmed Schmerzther 41(1): 21–6PubMedCrossRefGoogle Scholar
  35. Quinton TM, Kim S, Derian CK, Jin J, Kunapuli SP (2004) Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. J Biol Chem 279(18): 18434–9PubMedCrossRefGoogle Scholar
  36. Ramsay MA, Randall HB, Burton EC (2004) Intravascular thrombosis and thromboembolism during liver transplantation: antifibrinolytic therapy implicated? Liver Transpl 10(2): 310–4PubMedCrossRefGoogle Scholar
  37. Schoechl H (2006) Coagulation management in major trauma. Hamostaseologie 26(3 Suppl 1): S52–5Google Scholar
  38. Veres G, Radovits T, Schultz H, Lin LN, Hutter J, Weigang E, Szabolcs Z, Szabo G (2007) Effect of recombinant aprotinin on postoperative blood loss and coronary vascular function in a canine model of cardiopulmonary bypass. Eur J Cardiothorac Surg 32(2): 340–5PubMedCrossRefGoogle Scholar
  39. Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds LH Jr (1993) Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 106(1): 1–9 discussion 9–10PubMedGoogle Scholar
  40. Walsh PN, Rizza CR, Matthews JM et al. (1971) Epsilon-Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. Br J Haematol 20(5): 463–75PubMedCrossRefGoogle Scholar
  41. Xia VW, Steadman RH (2005) Antifibrinolytics in orthotopic liver transplantation: current status and controversies. Liver Transpl 11(1): 10–8PubMedCrossRefGoogle Scholar
  42. Zufferey P, Merquiol F, Laporte S, Decousus H, Mismetti P, Auboyer C, Samama CM, Molliex S (2006) Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology 105(5): 1034–46PubMedCrossRefGoogle Scholar

Literatur

  1. Alexander JW, Ogle CK, Stinnet JD et al. (1979) Fresh-frozen plasma versus plasma protein derivative as adjunctive therapy for patients with massive burns. J Trauma 19: 502–511PubMedGoogle Scholar
  2. Alvarez-Larrán A, Del Rio J, Ramírez C et al. (2004) Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 86: 246–251PubMedCrossRefGoogle Scholar
  3. Aquilar MI, Hart RG, Kase CS et al. (2007) Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 82: 82–92CrossRefGoogle Scholar
  4. Atance R, Pereira A, Ramírez B (2001) Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 41: 1548–1552PubMedCrossRefGoogle Scholar
  5. Baron BW, Mittendorf R, Baron JM (2001) Presurgical plasma exchange for severe factor V deficiency. J Clin Apheresis 16: 29–30PubMedCrossRefGoogle Scholar
  6. Bell WR, Braine HG, Ness PM, Kickler TS (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 325: 398–403PubMedCrossRefGoogle Scholar
  7. Bocanegra M, Bazan AA, Velarde NZ, Carpio M (1978) Clinical evaluation of the administration of large volumes of plasma in the treatment of severely burned children. Surgery 83: 558–563PubMedGoogle Scholar
  8. Bolton-Maggs PH, Perry DJ, Chalmers EA et al. (2004) The rare coagulation disorders — review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia 10: 593–628PubMedCrossRefGoogle Scholar
  9. Bolton-Maggs PHB, Colvin BT, Satchi G, Lee CA, Lucas GS (1994) Thrombogenic potential of factor XI concentrate. Lancet 344: 748–749PubMedCrossRefGoogle Scholar
  10. Borgman MA et al. (2007) The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 63: 805–813PubMedCrossRefGoogle Scholar
  11. Bux J, Sachs UJ (2007) The pathogenesis of transfusion-related acute lung injury (TRALI). Brit J Haematol 136: 788–799CrossRefGoogle Scholar
  12. Cardigan R, Allford S, Williamson L (2002) Levels of von Willebrand factor-cleaving protease are normal in methylene blue-treated freshfrozen plasma. Br J Haematol 117: 253–254PubMedCrossRefGoogle Scholar
  13. Casbard AC, Williamson LM, Murphy MF, Rege K, Johnson T (2004) The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A systematic review. Anaesthesia 59: 550–558PubMedCrossRefGoogle Scholar
  14. Caturelli E, Squillante MM, Andriulli A et al. (1993) Fine-needle liver biopsy in patients with severely impaired coagulation. Liver 13: 270–273PubMedCrossRefGoogle Scholar
  15. Chekrizova V, Murphy WG (2006) Solvent-detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med 16: 85–91PubMedCrossRefGoogle Scholar
  16. De la Rubia J, Arriaga F, Linares D et al. (2001) Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Brit J Haematol 114: 721–723CrossRefGoogle Scholar
  17. Deorari AK, Paul VK, Shreshta L, Singh M (1995) Symptomatic neonatal polycythemia: comparison of partial exchange transfusion with saline versus plasma. Ind Pediatr 32: 1167–1171Google Scholar
  18. Dupont J, Massiant F, Declerck N et al. (1996) Liver transplantation without the use of fresh frozen plasma. Anesth Analg 83: 681–686PubMedCrossRefGoogle Scholar
  19. Erber WN, Perry DJ (2006) Plasma and plasma products in the treatment of massive haemorrhage. Best Pract Res Clin Haematol 19: 97–112PubMedCrossRefGoogle Scholar
  20. Ewe K (1981) Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 26: 388–393PubMedCrossRefGoogle Scholar
  21. Faringer PD, Mullins RJ, Johnson RL, Trunkey DD (1993) Blood Component supplementation during massive transfusion of AS-1 red cells in trauma patients. J Trauma 34: 481–487PubMedCrossRefGoogle Scholar
  22. Favier R, Aoki N, de Moerloose P (2001) Congenital α2-plasmin inhibitor deficiency: a review. Brit J Haematol 114: 4–10CrossRefGoogle Scholar
  23. Fisher NC, Mutimer DJ (1999) Central venous cannulation in patients with liver disease and coagulopathy — a prospective audit. Crit Care Med 25: 481–485Google Scholar
  24. Fontana S, Kremer Hovinga JA, Lämmle B, Mansouri Taleghani B (2006) Treatment of thrombotic thrombocytopenic purpura. Vox Sang 90: 245–254PubMedCrossRefGoogle Scholar
  25. Friedman LS (1999) The risk of surgery in patients with liver disease. Hepatology 29: 1617–1623PubMedCrossRefGoogle Scholar
  26. Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B (1999) Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 81: 8–13PubMedGoogle Scholar
  27. Gazzard BG, Henderson JM, Williams R (1975) Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut 16: 617–620PubMedCrossRefGoogle Scholar
  28. Gistad CW (2004) Anaphylactic transfusion reactions. Curr Opin Hematol 10: 419–423CrossRefGoogle Scholar
  29. Gonzalez-Boullosa R, Ocampo-Martinez R, Alarcon-Martin MJ et al. (2005) The use of recombinant coagulation factor VII during haemarthroses and synovectomy in a patient with congenital factor V deficiency. Haemophilia 11: 167–170PubMedCrossRefGoogle Scholar
  30. Greinacher A, Kiefel V, Klüter H et al. (2007) Empfehlungen zur Thrombozytentransfusion der Thrombozyten-Arbeitsgruppe der DGTI, GTH und DGHO. Transfus Med Hemother 33: 528–543CrossRefGoogle Scholar
  31. Gross SJ, Filston HC, Anderson JC (1982) Controlled study of treatment for disseminated intravascular coagulation in the neonate. J Pediatr 100: 445–448PubMedCrossRefGoogle Scholar
  32. Hardy JF, de Moerloose P, Samama CM (2005) The coagulopathy of massive transfusion. Vox Sang 89: 123–127PubMedCrossRefGoogle Scholar
  33. Hellstern P (2004) Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 11: 346–350PubMedCrossRefGoogle Scholar
  34. Hellstern P, Haubelt H (2002) Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 2002 107(suppl 1): S3–S8CrossRefGoogle Scholar
  35. Hellstern P, Sachse H, Schwinn H, Oberfrank K (1992) Manufacture and in vitro characterization of solvent/detergent-treated human plasma. Vox Sang 63: 178–185PubMedCrossRefGoogle Scholar
  36. Hiippala S (1998) Replacement of massive blood loss. Vox Sang 74(suppl 2): 399–407PubMedGoogle Scholar
  37. Hiippala ST, Myllylahtera EM (1995) Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 81: 360–365PubMedCrossRefGoogle Scholar
  38. Johansson PI et al. (2007) Proactive administration of platelets and plasma for patients with a ruptured abdominal aortic aneurysm: evaluating a change in transfusion practice. Transfusion 47: 593–598PubMedCrossRefGoogle Scholar
  39. Kovacs M (2002) International normalised ratio and liver impairment. The Lancet 359: 695CrossRefGoogle Scholar
  40. Kujovich JL (2005) Hemostatic defects in end stage liver disease. Crit Care Med 21: 563–587Google Scholar
  41. Leese T, Holliday M, Watkins M et al. (2001) A multicentre controlled trial of high-volume fresh frozen plasma therapy in prognostically severe acute pancreatitis. Ann R Coll Surg Engl 73: 207–214Google Scholar
  42. Leese T, Holliday M, Heath D, Hall AW, Bell PR (1987) Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis. Brit J Surg 74: 907–911PubMedCrossRefGoogle Scholar
  43. Loirat C, Sonsino E, Hinglais N et al. (1988) Treatment of the childhood haemolytic uraemic syndrome with plasma. Pediatr Nephrol 2: 279–285PubMedCrossRefGoogle Scholar
  44. Martin RC 2nd, Jarnagin WR, Fong Y et al. (2003) The use of fresh frozen plasma after major hepatic resection for colorectal metastasis: is there a standard for transfusion? J Am Coll Surg 196: 402–409PubMedCrossRefGoogle Scholar
  45. Matsushita T, Saito H (2006) Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No, but they need a careful look. J Thromb Haemost 4: 721–723CrossRefGoogle Scholar
  46. McCall MM, Blackwell MM, Smyre JT et al. (2004) Fresh frozen plasma in the pediatric pump prime: a prospective, randomized trial. Ann Thorac Surg 77: 983–987PubMedCrossRefGoogle Scholar
  47. McVay PA, Toy PTCY (1991) Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 31: 164–171PubMedCrossRefGoogle Scholar
  48. McVay PA, Toy PTCY (1990) Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 94: 747–753PubMedGoogle Scholar
  49. Mintz PD, Neff A, MacKenzie M et al. (2006) A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 46: 1693–1704PubMedCrossRefGoogle Scholar
  50. Mueller MM, Bomke B, Seifried E (2002) Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver disease. Thromb Res 107: S9–S17PubMedCrossRefGoogle Scholar
  51. Murray DJ, Pennell BJ, Weinstein SL, Olson JD (1995) Packed red cells in acute blood loss: dilutional coagulopathy as a cause of surgical bleeding. Anesth Analg 81: 360–365CrossRefGoogle Scholar
  52. Murray DJ, Olsson J, Strauss R, Tinker JH (1988) Coagulation changes during packed red cell replacement of major blood loss. Anesthesiology 69: 839–845PubMedCrossRefGoogle Scholar
  53. Novakova IR, van Ginneken CA, Verbruggen HW, Haaenen C (1986) Factor XI kinetics after plasma exchange in severe factor XI deficiency. Haemostasis 16: 51–56PubMedGoogle Scholar
  54. O’Connell NM (2004) Factor XI deficiency. Semin Hematol 41: 76–81PubMedCrossRefGoogle Scholar
  55. Oliver WC, Beynen FM, Nuittall GA et al. (2003) Blood loss in infants and children for open heart operations: albumin 5% versus fresh-frozen plasma in the prime. Ann Thorac Surg 75: 1506–1512PubMedCrossRefGoogle Scholar
  56. Osborn DA, Evans N (2004) Early volume expansion for prevention of morbidity and mortality in very preterm infants. Cochrane Database Syst Rev 2: CD002005Google Scholar
  57. Ozier Y, Pessione F, Samain E, Courtois F (2003) Institutional variability in transfusion practice for liver transplantation. Anesth Analg 97: 671–679PubMedCrossRefGoogle Scholar
  58. Pereira A (2004) Methylene-blue-photoinactivated plasma and its contribution to blood safety. Transfusion 44: 948–949PubMedCrossRefGoogle Scholar
  59. Raphael JC, Chevret S, Hughes RAC, Annane D (2004) Plasma exchange for Guillain-Barre syndrome (Cochrane review). The Cochrane Library, Issue 2Google Scholar
  60. Reverter JC (2006) Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? Yes. J Thromb Haemost 4: 717–720PubMedCrossRefGoogle Scholar
  61. Rizzoni G, Claris-Appiani A, Edefonti A et al. (1988) Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 112: 284–290PubMedCrossRefGoogle Scholar
  62. Robert A, Chazouilleres O (1996) Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology 24: 1392–1394PubMedCrossRefGoogle Scholar
  63. Rock GA, Shumak KH, Buskard NA et al. (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis Study Group. N Engl J Med 325: 393–397PubMedCrossRefGoogle Scholar
  64. Runkel S, Haubelt H, Hitzler W, Hellstern P (2005) The quality of plasma collected by automated apheresis and of recovered plasma from leukodepleted whole blood. Transfusion 45: 427–432PubMedCrossRefGoogle Scholar
  65. Sachs UJ, Kauschat D, Bein G (2005) White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion 45: 1628–1631PubMedCrossRefGoogle Scholar
  66. Santagostino E, Mancuso ME, Morfini M et al. (2006) Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica 91: 634–639PubMedGoogle Scholar
  67. Schiff J, Misra M, Rendon G, Rothschild J, Schwaitzberg S (2005) Laparoscopic cholecystectomy in cirrhotic patients. Surg Endosc 19: 1278–1281PubMedCrossRefGoogle Scholar
  68. Shepard KV, Bukowski RM (1987) The treatment of thrombotic thrombocytopenic purpura with exchange transfusions, plasma infusions, and plasma exchange. Semin Hematol 24: 178–193PubMedGoogle Scholar
  69. Singh Y, Sawyer LS, Pinkoski LS et al. (2006) Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 46: 1168–1177PubMedCrossRefGoogle Scholar
  70. Solheim BG (2006) Universal pathogen-reduced plasma in elective open-heart surgery and liver resection. Clin Med Res 4: 207–217CrossRefGoogle Scholar
  71. Supapannachart S, Siripoonya P, Boonwattanasoontorn W, Kanjanavanit S (1999) Neonatal polycythemia: effects of partial exchange transfusion using fresh frozen plasma, hemaccel and normal saline. J Med Ass Thail 82(suppl 1): 82–85Google Scholar
  72. Tripodi A, Salerno F, Chantarangkul V et al. (2005) Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 41: 553–558PubMedCrossRefGoogle Scholar
  73. Williamson LM, Cardigan R, Prowse CV (2003) Methylene blue-treaated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 43: 1322–1329PubMedCrossRefGoogle Scholar
  74. Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ (2004) Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic Purpura. Transfus Med 14: 39–44PubMedCrossRefGoogle Scholar
  75. Youssef WI, Salazar F, Dasaranthy S, Beddow T, Mullen KG (2003) Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol 98: 1391–1394PubMedCrossRefGoogle Scholar

Literatur

  1. Aledort LM, Haschmeyer R, Petterson H and the Orthopaedic Outcome Study Group (1994) A longitudinal study of orthopaedic outcomes for severe factor VIII-deficient haemophiliacs. J Intern Med 236: 391–399PubMedCrossRefGoogle Scholar
  2. Anwar R, Miloszewski KJA (1999) Factor XIII deficiency. Brit J Haematol 107: 468–484CrossRefGoogle Scholar
  3. Astermark J, Morado M, Rocino A et al. (2006) Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 12: 363–371PubMedCrossRefGoogle Scholar
  4. Berntorp E (2006) Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3. Semin Thromb Hemost 32: 621–625PubMedCrossRefGoogle Scholar
  5. Blome M, Isgro F, Kiessling AH et al. (2005) Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 93: 1101–1107PubMedGoogle Scholar
  6. Bolton-Maggs PHB, Perry DJ, Chalmers EA et al. (2004) The rare coagulation disorders — review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia 10: 593–628PubMedCrossRefGoogle Scholar
  7. Bolton-Maggs PH, Wensley RT, Kernoff PBA et al. (1992) Production and therapeutic use of a factor XI concentrate from plasma. Thromb Haemost 67: 314–319PubMedGoogle Scholar
  8. Brackmann HH, Gormsen J (1977) Massive factor VIII infusion in haemophilic patients with factor VIII inhibitor, high responder. Lancet 2: 933PubMedCrossRefGoogle Scholar
  9. Bregenzer N, Caesar I, Andus T et al. (1999) Lack of clinical efficacy of additional factor XIII treatment in patients with steroid refractory colitis. Z Gastroenterol 37: 999–1004PubMedGoogle Scholar
  10. Bryant BJ, Klein HG (2007) Pathogen inactivation. The definitive safeguard for the blood supply. Arch Pathol Lab Med 131: 719–733Google Scholar
  11. Burnouf T (2007) Modern plasma fractionation. Transfus Med Rev 21: 101–117PubMedCrossRefGoogle Scholar
  12. Burnouf T, Padilla A (2006) Current strategies to prevent transmission of prions by human plasma derivatives. Transfus Clin Biol 13: 320–328PubMedCrossRefGoogle Scholar
  13. Burnouf-Radosevich M, Burnouf T (1992) A therapeutic highly purified factor XI concentrate from human plasma. Transfusion 32: 861–856PubMedCrossRefGoogle Scholar
  14. Canonico S (2003) The use of human fibrin glue in the surgical operations. Acta Bio Medica 74(Suppl 2): 21–25PubMedGoogle Scholar
  15. Carcao MD, Aledort L (2004) Prophylactic factor replacement in hemophilia. Blood Rev 18: 101–113PubMedCrossRefGoogle Scholar
  16. Chandler WL, Patel MA, Gravelle L et al. (2001) Factor XIIIa and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis 12: 101–108PubMedCrossRefGoogle Scholar
  17. Cohn EJ, Oncley JL, Strong LE, Hughes WL, Armstrong SH (1944) Chemical, clinical and immunological studies on the products of human plasma fractionation. I. The characterization of the protein fractions of human plasma. J Clin Invest 23: 417–432PubMedCrossRefGoogle Scholar
  18. Desmesmay K, Tissot E, Bulabois CE et al. (2002) Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases. Transplantation 74: 1190–1192CrossRefGoogle Scholar
  19. Egbring R, Seitz R, Gürten GV et al. (1988) Bleeding complicatins in heterozygotes with congenital factor XIII deficiency. In: Mossesson ME et al. (eds) Fibrinogen 3. Biochemistry, biological functions, gene regulation and expression. Amsterdam: Elsevier 341–346Google Scholar
  20. Ettingshausen CE, Kreuz W (2006) Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 12(Suppl 6): 102–106PubMedCrossRefGoogle Scholar
  21. Fischer K, van der Bom JG, Molho G et al. (2002) Prophylactic versus ondemand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 8: 745–752PubMedCrossRefGoogle Scholar
  22. Gazzard BG, Henderson JM, Williams R (1975) The use of fresh frozen plasma or a concentrate of factor IX as replacement therapy before liver biopsy. Gut 621–625Google Scholar
  23. Greinacher A, Kiefel V, Klüter H, Kroll H, Pötzsch B, Riess H (2006) Empfehlungen zur Thrombozytentransfusion der Thrombozyten-Arbeitsgruppe der DGTI, GTH und DGHO. Transfus Med Hemother 33: 528–543CrossRefGoogle Scholar
  24. Gringeri A, Mannucci PM, Italian Association of Haemophilia Centres (2005) Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 11: 611–619PubMedCrossRefGoogle Scholar
  25. Gödje O, Gallmeier U, Schelian M, Grünewald M, Mair H (2005) Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg 54: 26–33CrossRefGoogle Scholar
  26. Gödje O, Haushofer M, Lamm P, Reichart B (1998) The effect of factor XIII on bleeding in coronary surgery. Thorac Cardiovasc Surg 46: 263–267PubMedCrossRefGoogle Scholar
  27. Gouw SC, van der Bom JG, Marijke van den Berg H (2007a) Treatmentrelated risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 109: 4648–4654PubMedCrossRefGoogle Scholar
  28. Gouw SC, van der Bom JG, Auerswald G et al. (2007b) Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 109: 4693–4697PubMedCrossRefGoogle Scholar
  29. Hellstern P, Halbmayer WM, Köhler M, Seitz R, Müller-Berghaus G (1999) Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res 95(Suppl 1): S3–S6PubMedCrossRefGoogle Scholar
  30. Hoots WK, Nugent DJ (2006) Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 96: 433–440PubMedGoogle Scholar
  31. Julien D, Souillet HL, Faure M, Claudy A (1998) Coagulation factor XIII in scleroderma. Eur J Dermatol 8: 231–234Google Scholar
  32. Karges HE, Metzner HJ (1996) Therapeutic factor XIII preparations and perspectives for recombinant factor XIII. Semin Thromb Hemost 22: 427–436PubMedCrossRefGoogle Scholar
  33. Kessler CM (2006) Urgent reversal of warfarin with prothrombin complex concentrate: where are the evidence-based data? J Thromb Haemost 4: 963–966PubMedCrossRefGoogle Scholar
  34. Kistler P, Nitschmann H (1962) Large-scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang 7: 414–424PubMedCrossRefGoogle Scholar
  35. Kouides PA, Kulzer L (2001) Prophylactic treatment of severe factor X deficiency with prothrombin complex concentrate. Haemophilia 7: 220–223PubMedCrossRefGoogle Scholar
  36. Kreuz W, Meili E, Peter-Salonen K et al. (2005) Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency. Transfus Apheresis Sci 32: 247–253Google Scholar
  37. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM (2006) Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 4: 967–970PubMedCrossRefGoogle Scholar
  38. Lechler E (1999) Use of prothrombin complex concentrates for prophylaxis and treatment of bleeding episodes in patients with hereditary deficiency of prothrombin, factor VII, factor X, protein C, protein S, or protein Z. Thromb Res 95(Suppl 1): S39–S50PubMedCrossRefGoogle Scholar
  39. Lobel JS, Majumdar S, Kovats-Bell S (2004) Successful prophylactic treatment for bleeding in a girl with severe hereditary prothrombin deficiency using a prothrombin complex concentrate (Bebulin® VH). J Pediatr Hematol Oncol 26: 480–483PubMedCrossRefGoogle Scholar
  40. Lorenz R, Kienast R, Otto U et al. (2003) Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hapatol 15: 15–20CrossRefGoogle Scholar
  41. Lorenz R, Olbert P, Born P (1996) Factor XIII in chronic inflammatory bowel disease. Sem Thromb Hemost 22: 451–455CrossRefGoogle Scholar
  42. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357: 535–544PubMedCrossRefGoogle Scholar
  43. Mannucci PM (2004) Treatment of von Willebrand’s disease. N Engl J Med 351: 683–694PubMedCrossRefGoogle Scholar
  44. Mannucci PM, Franchi F, Dioguardi N (1976) Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet 2: 542–545PubMedCrossRefGoogle Scholar
  45. Michiels JJ, van Vliet HH, Berneman Z et al. (2007) Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients with von Willebrand disease types 1, 2 and 3. Clin Appl Thromb Hemost 13: 14–34PubMedCrossRefGoogle Scholar
  46. Peyvandi F, Haertel S, Knaub S, Mannucci PM (2006) Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia of hypofibrinogenemia. J Thromb Haemost 4: 1634–1637PubMedCrossRefGoogle Scholar
  47. Plug I, van der Bom JG, Peters M et al. (2004) Thirty years of hemophilia treatment in the Netherlands, 1972–2001. Blood 104: 3494–3500PubMedCrossRefGoogle Scholar
  48. Poon MC (2001) Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opin Hematol 8: 312–318PubMedCrossRefGoogle Scholar
  49. Preston FE, Laidlaw ST, Sampson B, Kitchen S (2002) Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Brit J Haematol 116: 619–624CrossRefGoogle Scholar
  50. Royal S, Schramm W, Berntorp E et al. (2002) Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 8: 44–50PubMedCrossRefGoogle Scholar
  51. Scharrer I (2005) Leberzirrhose und Gerinnungsstörungen. Hämostaseologie 25: 205–208PubMedGoogle Scholar
  52. Schexneider KI (2004) Fibrin sealants in surgical or traumatic hemorrhage. Curr Opin Hematol 11: 232–326CrossRefGoogle Scholar
  53. Schimpf K, Fischer B, Rothmann P (1977) Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study. Scand J Haematol Suppl 30: 79–80PubMedGoogle Scholar
  54. Schopgen G, Bonik K, Rosenkranz G (1994) Fibrinogensubstitution mit Haemocomplettan HS. Hämostaseologie 14: 140–148Google Scholar
  55. Schramm W, Scharrer I (2000) Konsensus Empfehlungen zur Hämophiliebehandlung in Deutschland. GTH Hämophiliekommission, update 1999. Hämophilieblätter 34: 62–62Google Scholar
  56. Spence RK, Mintz PD (2005) Transfusion in trauma, surgery and critical care. In: Mintz PD (ed) Transfusion therapy. Bethesda: AABB Press, p 203–241Google Scholar
  57. Steen Carlsson K, Hojgard S, Glomstein A et al. (2003) On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia 9: 555–566PubMedCrossRefGoogle Scholar
  58. Tengborn L, Berntorp E (1998) Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B. Haemophilia 4: 56–59PubMedCrossRefGoogle Scholar
  59. Tosetto A, Rodeghiero F, Gatto E, Manotti C, Poli T (1995) An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophophamide. Am J Hematol 48: 34–39PubMedCrossRefGoogle Scholar
  60. Van den Berg HM, Fischer K, van der Bom JG, Rosendaal G, Mauser-Bunschoten EP (2002) Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies. Haemophilia 8(Suppl 2): 43–46PubMedCrossRefGoogle Scholar
  61. Venturi C, Zendri E, Santini M et al. (2004) Sceredema of Buschke: remission with factor XIII treatment. Int J Tiissue React 26: 25–28Google Scholar
  62. Vigué B, Ract C, Tremey B et al. (2007) Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 33: 721–725PubMedCrossRefGoogle Scholar
  63. Wettstein P, Haeberli A, Stutz M et al. (2004) Decreased factor XIII availability for thrombin and early loss of clot firmness in patients with unexplained intraoperative bleeding. Anesth Analg 99: 1564–1569PubMedCrossRefGoogle Scholar

Literatur

  1. Abshire T, Kenet G (2004) Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2: 899–909PubMedCrossRefGoogle Scholar
  2. Ahonen J, Jokela R (2005) Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth 94: 592–595PubMedCrossRefGoogle Scholar
  3. Aledort LM (2004) Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. Thromb Haemost 2: 1700–8CrossRefGoogle Scholar
  4. Almeida AM, Khair K, Hann I, Liesner R (2003) The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 121, 477–481PubMedCrossRefGoogle Scholar
  5. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E; FENOC Study Group (2007) A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 109: 546–51PubMedCrossRefGoogle Scholar
  6. Berntorp E, Shapiro A, Astermark J et al. (2006) Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 12(Suppl 6): 1–7PubMedCrossRefGoogle Scholar
  7. Bijsterveld NR, Moons AH, Boekholdt SM, van Aken BE, Fennema H, Peters RJ, Buller HR, Levi M (2002) Ability of recombinant factor VIIa to ! reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106: 2550–4PubMedCrossRefGoogle Scholar
  8. Boffard KD, Riou B, Warren B et al. and the NovoSeven Trauma Study Group (2005) Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 59: 8–15PubMedCrossRefGoogle Scholar
  9. Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT (2002) Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 124: 852–4PubMedCrossRefGoogle Scholar
  10. Chan S, Kong M, Minning DM, Hedner U, Marder VJ (2003) Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin. J Thromb Haemost 1: 760–5PubMedCrossRefGoogle Scholar
  11. Diprose P, Herbertson MJ, O’Shaughnessy D, Gill R (2005) Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 95: 596–602PubMedCrossRefGoogle Scholar
  12. Ekert H, Brizard C, Eyers R, Cochrane A, Henning R (2006) Elective administration of low dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypasssurgery for congenital heart disease does not shorten time to chest closure or reduce blood loss or need for transfusions: a randomized, double-blind, parallel group, placebo controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic therapy. Blood Coagul Fibrinol 17: 389–95CrossRefGoogle Scholar
  13. Firozvi K, Deveras RA, Kessler CM (2006) Reversal of low-molecularweight heparin-induced bleeding in patients with pre-existing hypercoagulable states with human recombinant activated factor VII concentrate. Am J Hematol 81: 582–9PubMedCrossRefGoogle Scholar
  14. Franchini M, Salvagno GL, Lippi G (2006) Inhibitors in mild/moderate haemophilia A: an update.Thromb Haemost 96: 113–8Google Scholar
  15. Girolami A, Randi ML, Ruzzon E, Zanon E, Girolami B (2005) Myocardial infarction, other arterial thrombosis and invasive coronary procedures, in hemaophilia B: a critical evaluation of reported cases. J Thromb Thrombolysis 20: 43–6PubMedCrossRefGoogle Scholar
  16. Hay CR, Negrier C, Ludlam CA (1997) The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 78: 1463–1467PubMedGoogle Scholar
  17. Hedner U, Erhardtsen E (2002) Potential role of for rhFVIIa in transfusion medicine. Transfusion 42: 114–124PubMedCrossRefGoogle Scholar
  18. Hoffman M, Monroe DM (2001) A cell based model of hemostasis. Thromb Haemost 88: 958–65Google Scholar
  19. Hollnberger H, Gruber E, Seelbach-Goebel B (2005) Major Post-Partum Hemorrhage and Treatment with Recombinant Factor VIIa. Anesth Analg 101: 1186–1187Google Scholar
  20. Huvers F, Slappendel R, Benraad B, van Hellemondt G, van Kraaij M (2005) Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med 63: 184–6PubMedGoogle Scholar
  21. Ingerslev J, Knudsen L, Hvid I, Tange MR, Fredberg U, Sneppen O (1997) Use of recombinant factor VIIa in surgery in factor-VII-deficient patients. Haemophilia 3: 215–18CrossRefGoogle Scholar
  22. Jurlander B, Thim L, Klausen N et al. (2001) Recombinant activated factor VII (rhFVIIa): Characterisation, manufacturing and clinical development. Sem Thromb Haemost 27: 373–383CrossRefGoogle Scholar
  23. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams Z, Kenet G (2006) Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 95: 600–5PubMedGoogle Scholar
  24. Karkouti K, Yau TM, Riazi S et al. (2006) Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Can J Anaesth 53: 802–9PubMedCrossRefGoogle Scholar
  25. Karkouti K, Beattie WS, Wijeysundera DN et al. (2005) Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 45: 26–34PubMedCrossRefGoogle Scholar
  26. Kenet G, Lubetzk A, Luboshitz J, Martinowitz U (2003) A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 1: 450–455PubMedCrossRefGoogle Scholar
  27. Key NS, Christie B, Henderson N, Nelsestuen GL (2002) Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 88: 60–65PubMedGoogle Scholar
  28. Leissinger CA, Becton DL, Ewing NP, Valentino LA (2007) Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 13: 249–55PubMedCrossRefGoogle Scholar
  29. Levy JH, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ (2006) Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhoise, or severe traumatic injury: review of safety profile. Transfusion 46: 919–33PubMedCrossRefGoogle Scholar
  30. Lodge JP, Jonas S, Jones RM et al. for the rFVIIa OLT Study Group (2005) Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 11: 973–9PubMedCrossRefGoogle Scholar
  31. Lodge JP, Jonas S, Oussoultzoglu E et al. (2005) Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 102: 269–75PubMedCrossRefGoogle Scholar
  32. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, Laurian Y, Kasper CK, Mannucci PM (1998) A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia 4: 790–798PubMedCrossRefGoogle Scholar
  33. Mayer SA, Brun NC, Begtrup K et al.; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial investigators (2005) Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352: 777–85PubMedCrossRefGoogle Scholar
  34. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M (1996) Reexploration for Bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 111: 1037–46PubMedCrossRefGoogle Scholar
  35. Ng HJ, Koh LP, Lee LH (2003) Successful control of postsurgical bleeding by recombinant factor VIIa in a renal failure patient given low molecular weight heparin and aspirin. Ann Hematol 82: 257–8PubMedGoogle Scholar
  36. Nurden AT, George JN (2001) Inherited abnormalities of the platelet membrane: Glanzmann Thrombasthenia, Bernard-Soulier-Syndrome, and other disorders. In: Colman R (ed) Haemostsasis and Thrombosis. Philadelphia: Lippincott Williams & Wilkins, p 987 ppGoogle Scholar
  37. O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM (2006) Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295: 293–8PubMedCrossRefGoogle Scholar
  38. Peerlinck K, Vermylen J (1999) Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor. Thromb Haemost 82: 1775–6PubMedGoogle Scholar
  39. Poon MC (2007) The evidence for the use of recombinant human activated factor vii in the treatment of bleeding patients with quantitative and qualitative platelet disorders. Transfus Med Rev 21: 223–36PubMedCrossRefGoogle Scholar
  40. Romagnoli S, Bevilacqua S, Gelsomino S, Pradella S, Ghili L, Rostagno C, Gensini GF, Sorbara C (2006) Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 102: 1320–6PubMedCrossRefGoogle Scholar
  41. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM (2006) A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 4: 367–71PubMedCrossRefGoogle Scholar
  42. Scharrer I, Großmann R (2000) Erworbene Hemmkörper-Hämophilie. Anästhesist 49: 34–42CrossRefGoogle Scholar
  43. Schneiderman J, Rubin E, Nugent DJ, Young G (2007) Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 13: 244–8PubMedCrossRefGoogle Scholar
  44. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA (1998) Prospective, randomised trial of two doses of rFVIIa (NovoSeven®) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 80: 773–778PubMedGoogle Scholar
  45. Spahn DR, Cerny V, Coats TJ et al.; Task Force for Advanced Bleeding Care in Trauma (2007) Management of bleeding following major trauma: a European guideline. Crit Care 11: R17PubMedCrossRefGoogle Scholar
  46. Stepinska J, Banaszewski M, Konopka A, Szajewski T (2002) Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban. Thromb Haemost 87: 355–6PubMedGoogle Scholar
  47. Turecek PL, Varadi K, Keil B, Negrier C, Berntorp E, Astermark J, Bordet JC, Morfini M, Linari S, Schwarz HP (2003) Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 33: 16–22PubMedCrossRefGoogle Scholar
  48. Villar A, Aronis S, Morfini M, Santagostino E, Auerswald G, Thomsen HF, Erhardtsen E, Giangrande PLF (2004) Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 10: 352–359PubMedCrossRefGoogle Scholar
  49. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR (2006) Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding 73-a European perspective. Crit Care 10(4): R120PubMedCrossRefGoogle Scholar
  50. Virchis A, Hughes C, Berney S (2004) Severe gastrointestinal hemorrhage responding to recombinant factor VIIa in a Jehovas witness with refractory immune thrombocytopenia. Haematology J 5: 281–282CrossRefGoogle Scholar
  51. von Heymann C, Jonas S, Spies C, Wernecke KD, Ziemer S, Janssen D, Koscielny J (2008) Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data. Crit Care 12: R14CrossRefGoogle Scholar
  52. von Heymann C, Redlich U, Jain U et al. (2005) Recombinant activated factor VII for refractory bleeding after cardiac surgery—a retrospective analysis of safety and efficacy. Crit Care Med 33: 2241–6CrossRefGoogle Scholar
  53. Vorstand und wissenschaftlicher Beirat der Bundesärztekamme (Hrsg.) (2003) Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten, 3. überarbeitete Aufl. Köln: Deutscher Ärzte-Verlag, S 134Google Scholar
  54. Young G, Shafer FE, Rojas P, Seremetis S (2008). Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg (−1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia;14:287–94.PubMedCrossRefGoogle Scholar

Literatur

  1. Anderson NA, Gray S, Copplestone JA et al. (1996) A prospectice randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions. Transfus Med 6: 33–39Google Scholar
  2. Andreu G, Morel P, Forestier F, Debeir J, Rebibo D, Janvier G, Hervé P (2002) Hemovigilance netork in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion 42: 1356–1364PubMedCrossRefGoogle Scholar
  3. Arnold DM, Heddle N M, Kulczycky M, Carruthers J, Sigouin C, Blajchman MA (2006) In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers Transfusion 46: 257–264PubMedCrossRefGoogle Scholar
  4. Beilin Y, Zahn J, Comerford M (1997) Safe epidural analgesia in thirty patients with platelet counts between 69,000 and 98,000 mm(-3). Anesth Analg 85: 385–388PubMedCrossRefGoogle Scholar
  5. Benjamin RJ, Antin JH (1999) ABO incompatible bone marrow transplantation: the transfuson of incompatible plasma my exacerbate regimen-related toxicity. Transfusion 39: 1273–4PubMedCrossRefGoogle Scholar
  6. Benjamin RJ, Mcgurk S, Ralston MS et al. (1999) AB0 incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion 39: 179–87PubMedCrossRefGoogle Scholar
  7. Bierling P, Fromont P, Bettaieb A, Duedari N (1989) Anti-Br(a) antibodies in the French population [letter]. Br J Haematol 73: 428–429PubMedCrossRefGoogle Scholar
  8. Blumberg N, Heal JM, Hick GL et al. (2001) Association of AB0-mismatched platelet transfusions with morbidity and mortality in cardiac surgery. Transfusion 41: 790–3PubMedCrossRefGoogle Scholar
  9. Bravo AA, Sheth SG, Chopra S (2001) Liver biopsy. N Engl J Med 344: 495–500PubMedCrossRefGoogle Scholar
  10. Bux J, Becker F, Seeger W, Kilpatrick D, Chatman J, Waters A (1996) Transfusion related acute lung injury due to HLA-A2-specific antibodies in recipient and NB1-specific antibodies in donor blood. Br J Heamatol 93: 707–71CrossRefGoogle Scholar
  11. Contreras M (1998) Final statement from the consensus conference on platelet transfusion. Transfusion 38: 796–797PubMedCrossRefGoogle Scholar
  12. Delaflor-Weiss E, Mintz PD (2000) The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 14: 180–196PubMedCrossRefGoogle Scholar
  13. Duquesnoy RJ, Anderson AJ, Tomasulo PA et al. (1979) AB0 compatibility and platelet transfusions of alloimmunized thrombocytopenic patients. Blood 54: 595–9Google Scholar
  14. Edelson RN, Chernik NL, Posner JB (1974) Spinal subdural hematomas complicating lumbar puncture. Arch Neurol 31: 134–137PubMedGoogle Scholar
  15. Gelb AB, Leavitt AD (1997) Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion 37: 624–630PubMedCrossRefGoogle Scholar
  16. Godeau B, Chevret S, Varet B et al.; rench ATIP Study Group (2002) Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 359: 23–9PubMedCrossRefGoogle Scholar
  17. Greinacher A, Kiefel V, Klüter H, Kroll H, Pötzsch B, Riess H (2006) Empfehlungen zur Thrombozytentransfusion der Thrombozyten-Arbeitsgruppe der DGTI, GTH und DGHO. Transfus Med Hemoth 33: 528–543CrossRefGoogle Scholar
  18. Heal JM, Blumberg N, Masel D (1987) An evaluation of crossmatching, HLA, and AB0 matching for platelet transfusions to refractory patients. Blood 70: 23–30PubMedGoogle Scholar
  19. Heal JM, Blumberg N (2004) Optimizing platelet transfusion therapy. Blood 18(3): 149–65 [review]CrossRefGoogle Scholar
  20. Heal JM, Masel D, Rowe JM et al. (1993) Circulating immune complexes involving the AB0 system after platelet transfusion. Br J Haematol 85: 566–572PubMedCrossRefGoogle Scholar
  21. Heal JM, Rowe JM, Blumberg N (1993) AB0 and platelet transfusion revisited. Ann Hematol 66: 309–14PubMedCrossRefGoogle Scholar
  22. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP (1997) Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 15: 1143–9PubMedGoogle Scholar
  23. Heddle NM, Blajchman MA, Meyer RM et al. (2002) A randomised controlled trial comparing the frequency of acute reactions to plasmaremoved platelets and prestorage WBC-reduced platelets. Transfusion 42: 556–566PubMedCrossRefGoogle Scholar
  24. Hew-Wing P, Rolbin SH, Hew E, Amato D (1989) Epidural anaesthesia and thrombocytopenia. Anesthesia 44: 775–777CrossRefGoogle Scholar
  25. Holness L, Knippen MA, Simmons L, Lachenbruch PA (2004) Fatalities caused by TRALI. Transfus Med Rev 18: 184–188PubMedCrossRefGoogle Scholar
  26. Howard JE, Perkins HA (1978) The natural history of alloimmunization to platelets. Transfusion 18: 496–503PubMedCrossRefGoogle Scholar
  27. Kickler T, Braine H, Piantadosi S, Ness PM, Herman JH, Rothko K (1990) A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombcytopenic patients. Blood 75: 313–316PubMedGoogle Scholar
  28. Kiefel V, Bassler D, Kroll H et al. (2006) Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 107: 3761–3763PubMedCrossRefGoogle Scholar
  29. Kiefel V, König C, Kroll H, Santoso S (2001) Platelet alloantibodies in transfused patients. Transfusion 41: 766–770PubMedCrossRefGoogle Scholar
  30. Klumpp TR, Herman JH, Innis S et al. (1996) Factors associated with response to platelet transfusions following hematopoietic stem cell transplantation. Bone Marrow Transplant 17: 1035–41PubMedGoogle Scholar
  31. Klüter H, Bubel S, Kirchner H, Wilhelm D (1999) Febrile and allergic transfusion reactions after transfusion of white cell-poor platelet preparations. Transfusion 39: 1179–83PubMedCrossRefGoogle Scholar
  32. Klüter H, Dörges I, Maass E, Wagner T, Bartels H, Kirchner H (1996) In-vivo evaluation of random donor platelet concentrates from pooled buffy coats. Ann Hematol 73: 85–89PubMedCrossRefGoogle Scholar
  33. Kroll H, Carl B, Santoso S, Bux J, Bein G (2001) Workshop report on the genotyping of blood cell alloantigens. Transfusion Medicine 11: 211–219PubMedCrossRefGoogle Scholar
  34. Kroll H, Kiefel V, Santoso S (1998) Clinical aspects and typing of platelet alloantigens. Vox Sanguinis 74: 345–354PubMedGoogle Scholar
  35. Kroll H, Kiefel V, Giers G, Bald R, Hoch J, Hanfland P, Hansmann M, Mueller-Eckhardt C (1994) Maternal intravenous immunoglobulin treatment does not prevent intracranial haemorrhage in fetal alloimmune thrombocytopenia. Transfusion Medicine 4: 293–296PubMedCrossRefGoogle Scholar
  36. Kroll H, Yates J, Santoso S (2005) Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens. Transfusion 45: 353–8PubMedCrossRefGoogle Scholar
  37. Langenscheidt F, Kiefel V, Santoso S, Mueller-Eckhardt C (1988) Platelet transfusion refractoriness associated with two rare platelet-specific alloantibodies (anti-Bak(a) and anti-Pl(A2)) and multiple HLA-antibodies. Transfusion 28: 597–600PubMedCrossRefGoogle Scholar
  38. Lawrence JB, Yomtovian RA, Hammons T, Masarik SR, Chongkolwatana V, Creger RJ, Manka A, Lazarus HM (2001) Lowering the prophylactic platelet transfusion threshold: a prospective analysis. Leuk Lymphoma 41: 67–76PubMedCrossRefGoogle Scholar
  39. Lee EJ, Schiffer CA (1989) AB0 incompatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion 29: 384–389PubMedCrossRefGoogle Scholar
  40. Lee EJ, Norris D, Schiffer CA (1987) Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion. Transfusion 27: 245–247PubMedCrossRefGoogle Scholar
  41. Lin Y, Callum JL, Coovadia AS, Murphy PM (2002) Transfusion of AB0 non identiccal platelets is not associated with adverse clinical outcomes in cardiovascular surgery patients. Transfusion 42: 166–72PubMedCrossRefGoogle Scholar
  42. McFarland J, Anderson AJ, Slichter SJ (1989) Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates. Br J Haematol 73: 380–386PubMedCrossRefGoogle Scholar
  43. Miller AB, Hoogstraten B, Stachet M et al. (1981) Reporting results of cancer treatment. Cancer 47: 207–214PubMedCrossRefGoogle Scholar
  44. Mueller-Eckhardt C, Förster C, Kayser W et al. (1982) Alloimmunthrombozytopenie der Neugeborenen durch thrombozytenspezifische Antikörper (Anti-PlA1). Dtsch Med Wochenschr 107: 216–219PubMedCrossRefGoogle Scholar
  45. Mueller-Eckhardt C, Kiefel V, Grubert A, Kroll H, Weisheit M, Schmidt S, Mueller-Eckhardt G, Santoso S (1989) 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1: 363–366PubMedCrossRefGoogle Scholar
  46. Munksgaard L, Albjerg L, Lillevang ST, Gahrn-Hansen B, Georgsen J (2004) Detection of bacterial contamination of platelet components: six years’ experience with the BacT/Alert system. Transfusion 44: 1166–1173PubMedCrossRefGoogle Scholar
  47. Murphy MF, Waters AH (1985) Immunological aspects of platelet transfusions. Br J Haematol 60: 409–414PubMedCrossRefGoogle Scholar
  48. Navarro JT, Hernandez JA, Ribera JM, Sancho JM, Oriol A, Pujol M, Milla F, Feliu E (1998) Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL. Haematologica 83: 998–1000PubMedGoogle Scholar
  49. O’Connell BA, Lee EJ, Rothko K, Hussein MA, Schiffer CA (1992) Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates. Blood 79: 527–531PubMedGoogle Scholar
  50. Petz LD, Garratty G, Calhoun L et al. (2000) Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 40: 1446–1456PubMedCrossRefGoogle Scholar
  51. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbui T, Mandelli F, Sirchia G (1997) The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. N Engl J Med 337: 1870–5PubMedCrossRefGoogle Scholar
  52. Roth WK, Seifried E (2002) The German Experience with NAT. Transfusion Med 12: 255–258CrossRefGoogle Scholar
  53. Sagmeister M, Oec L, Gmur J (1999) A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 93: 3124–6PubMedGoogle Scholar
  54. Samama CM, Bastien O, Forestier F et al. (2002) Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001 — summary statement. Can J Anesth 49: S26–35PubMedGoogle Scholar
  55. Samama CM, Djoudi R, Lecompte T, Nathan-Denizot N, Schved J-F, and the AFSSAPS Expert Group (2005) Perioperative platelet transfusion: recommendations of the agence française de sécurité sanitaire des produits de santé (AFSSaPS) 2003. Can J Anesth 52: 30–37PubMedCrossRefGoogle Scholar
  56. Slichter SJ (2004) Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfusion Medicine Reviews 18: 153–167PubMedCrossRefGoogle Scholar
  57. Schnaidt M, Northoff H, Wernet D (v) Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic disorders. Transfus Med 6: 111–114Google Scholar
  58. Stainsby D, MacLennan S, Hamilton PJ (2000) Management of massive blood loss: a template guide. Br J Anaesth 85: 487–491PubMedGoogle Scholar
  59. Stanworth SJ, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF (v) Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 4: CD004269 [review]Google Scholar
  60. Stark K, Werner E, Seeger E, Offergeld R, Altmann D, Kramer MH (2002) Infections with HIV, HBV, and HCV among Blood Donors in Germany 1998 and 1999. Infus Ther Transfus Med 29: 305–307Google Scholar
  61. Strindberg J, Berlin G (1996) Transfusion of platelet concentrates — clinical evaluation of two preparations. Eur J Haematol 57: 307–311PubMedCrossRefGoogle Scholar
  62. Tinmouth A, Tannock IF, Crump M, Tomlinson G, Brandwein J, Minden M, Sutton D (2004) Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion 44: 1711–1719PubMedCrossRefGoogle Scholar
  63. Vandermeulen EP, Van Aken H, Vermylen J (1994) Anticoagulants and spinal-epidural anaesthesia. Anesth Analg 79: 1165–1177PubMedCrossRefGoogle Scholar
  64. Wandt H, Ehninger G, Gallmeier WM (2001) New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist 6: 446–450 [review]PubMedCrossRefGoogle Scholar
  65. Wandt H, Frank M, Ehninger G, Schneider C et al. (1998) Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 91: 3601–3606PubMedGoogle Scholar
  66. Weis SM, Hert RC, Gianola FJ, Clark JG, Crawford SW (1993) Complications of fiberoptic bronchoscopy in thrombocytopenic patients. Chest 104: 1025–1028CrossRefGoogle Scholar
  67. Williamson LM, Hackett G, Rennie J etn al. (1998) The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood 92: 2280–2287PubMedGoogle Scholar
  68. Zalneraitis EL, Young RSK, Krishnamoorthy KS (1979) Intracranial hemorrhage in utero as a complication of isoimmune thrombocytopenia. J Pediatr 95: 611–614PubMedCrossRefGoogle Scholar

Literatur

  1. Abkowitz JL, Chen J (2007) Studies of c-Mpl function distinguish the replication of hematopoietic stem cells from the expansion of differentiating clones. Blood 109: 5186–5190PubMedCrossRefGoogle Scholar
  2. Avecilla ST, Hattori K, Heissig B et al. (2004) Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 10: 64–71PubMedCrossRefGoogle Scholar
  3. Basser RL, O’Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM, Cohen B, Begley CG (2002) Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 99: 2599–2602PubMedCrossRefGoogle Scholar
  4. Basser RL, Underhill C, Davis I et al. (2000) Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol 18: 2852–2861PubMedGoogle Scholar
  5. Basser RL, Rasko JE, Clarke K et al. (1997) Randomized, blinded, placebocontrolled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 89: 3118–3128 [erratum in Blood 1997; 90(6): 2513]PubMedGoogle Scholar
  6. Basser RL, Rasko JE, Clarke K et al. (1996) Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 348: 1279–1281PubMedCrossRefGoogle Scholar
  7. Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J (2000) Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 26: 141–145PubMedCrossRefGoogle Scholar
  8. Bussel JB, Cheng G, Saleh MN et al. (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357(22): 2237–47PubMedCrossRefGoogle Scholar
  9. Bussel JB, Cheng G, Saleh M, Kovaleva L, Stone N, Mayer B, Jenkins J, Provan A (2006a) Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor. ASH Annual Meeting Abstracts 108: 475Google Scholar
  10. Bussel JB, Kuter DJ, George JN et al. (2006b) AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355: 1672–1681PubMedCrossRefGoogle Scholar
  11. Cerneus D, Brown K, Harris R et al. (2005) Stimulation of Platelet Production in Healthy Volunteers by a Novel Pegylated Peptide-Based Thrombopoietin (TPO) Receptor Agonist. ASH Annual Meeting Abstracts 106: 1249–Google Scholar
  12. Cwirla SE, Balasubramanian P, Duffin DJ et al. (1997) Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 276: 1696–1699PubMedCrossRefGoogle Scholar
  13. de Sauvage FJ, Hass PE, Spencer SD et al. (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369: 533–538PubMedCrossRefGoogle Scholar
  14. Desjardins RE, Tempel DL, Lucek R, Kuter DJ (2006) Single and Multiple Oral Doses of AKR-501 (YM477) Increase the Platelet Count in Healthy Volunteers. ASH Annual Meeting Abstracts 108: 477Google Scholar
  15. Doshi PD, Giri JG, Abegg AL et al. (2001) Promegapoietin, a family of chimeric growth factors, supports megakaryocyte development through activation of IL-3 and c-Mpl ligand signaling pathways. Exp Hematol 29: 1177–1184PubMedCrossRefGoogle Scholar
  16. Douglas VK, Tallman MS, Cripe LD, Peterson LC (2002) Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol 117: 844–850PubMedCrossRefGoogle Scholar
  17. Fibbe WE, Heemskerk DP, Laterveer L, Pruijt JF, Foster D, Kaushansky K, Willemze R (1995) Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice. Blood 86: 3308–3313PubMedGoogle Scholar
  18. Frederickson S, Renshaw MW, Lin B et al. (2006) A rationally designed agonist antibody fragment that functionally mimics thrombopoietin. Proc Natl Acad Sci USA 103: 14307–14312PubMedCrossRefGoogle Scholar
  19. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL (2007) Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 109: 4739–4741PubMedCrossRefGoogle Scholar
  20. Kai M, Motoki K, Yoshida H et al. (2006) Domain Subclass Conversion Improved Activity of Anti-Mpl Agonist Antibodies in the Form of Whole IgG. ASH Annual Meeting Abstracts 108: 1134Google Scholar
  21. Kelemen E, Cserhati I, Tanos B (1958) Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol 20: 350–355PubMedCrossRefGoogle Scholar
  22. Kuter DJ, Bussel JB, Lyons RM et al. (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371(9610): 395–403PubMedCrossRefGoogle Scholar
  23. Kuter DJ (2007) New thrombopoietic growth factors. Blood 109: 4607–4616PubMedCrossRefGoogle Scholar
  24. Kuter DJ, Goodnough LT, Romo J, DiPersio J, Peterson R, Tomita D, Sheridan W, McCullough J (2001) Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 98: 1339–1345PubMedCrossRefGoogle Scholar
  25. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98: 3241–3248PubMedCrossRefGoogle Scholar
  26. McHutchison JG, Dusheiko G, Shiffman ML et al. (2007) Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C. N Engl J Med 357: 2237–47CrossRefGoogle Scholar
  27. McHutchinson JG, Afdhal NH, Dusheiko G et al. (2006) Eltrombopag, an oral platelet growth factor, facilitates initiation of interferon therapy in subjects with HCV associated thrombocytopenia: results from a phase II placebo controlled, double-blind, dose-ranging study. Hepatology 44: Abstract 692AGoogle Scholar
  28. Nash RA, Kurzrock R, DiPersio J et al. (2000) A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 6: 25–34PubMedCrossRefGoogle Scholar
  29. Orita T, Tsunoda H, Yabuta N et al. (2005) A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood 105: 562–566PubMedCrossRefGoogle Scholar
  30. Scheding S, Bergmann M, Shimosaka A, Wolff P, Driessen C, Rathke G, Jaschonek K, Brugger W, Kanz L (2002) Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion 42: 321–327PubMedCrossRefGoogle Scholar
  31. Schuster MW, Beveridge R, Frei-Lahr D et al. (2002) The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol 30: 1044–1050PubMedCrossRefGoogle Scholar
  32. Somlo G, Sniecinski I, ter Veer A et al. (1999) Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood 93: 2798–2806PubMedGoogle Scholar
  33. Vadhan-Raj S, Patel S, Bueso-Ramos C et al. (2003) Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 21: 3158–3167PubMedCrossRefGoogle Scholar
  34. Vadhan-Raj S, Murray LJ, Bueso-Ramos C et al. (1997) Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 126: 673–681PubMedGoogle Scholar
  35. Vadhan-Raj S (1998) Recombinant human thrombopoietin: clinical experience and in vivo biology. Semin Hematol 35: 261–268PubMedGoogle Scholar
  36. Wang B, Nichol JL, Sullivan JT (2004) Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 76: 628–638PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • J. Koscielny
    • 1
  • C. Jámbor
    • 2
  • C. F. Weber
    • 3
  • P. Hellstern
    • 4
  • C. von Heymann
    • 5
  • A. Greinacher
    • 6
  • H.-G. Kopp
    • 7
  • R. Möhle
    • 8
  • L. Kanz
    • 7
  1. 1.Institut für TransfusionsmedizinCharité-Universitätsmedizin BerlinBerlin
  2. 2.Klinikum Großhadern, Klinik für Anästhesiologie, Arbeitsgruppe Perioperative HämostaseUniversität MünchenMünchen
  3. 3.Institut für molekulare Herz-KreislaufforschungUniversitätsklinikum AachenAachen
  4. 4.Klinikum der Stadt LudwigshafenInstitut für Hämostaseologie und TransfusionsmedizinLudwigshafen
  5. 5.Campus Virchow-Klinikum/Campus Charité Mitte, Klinik für Anästhesiologie mit Schwerpunkt operative IntensivmedizinCharité-Universitätsmedizin BerlinBerlin
  6. 6.Institut für Immunologie und TransfusionsmedizinErnst Moritz Arndt Universität GreifswaldGreifswald
  7. 7.Innere Medizin IIUniversitätsklinikum TübingenTübingen
  8. 8.Medizinische Klinik IIUniversitätsklinikum TübingenTübingen

Personalised recommendations